About 100 guests from 36 countries met on the XVIII. MetaSystems Distributor Meeting (DM) in November to exchange experiences and to get to know new trends and developments at MetaSystems.

Our internet site may contain information that is not approved in all countries or regions. To ensure accuracy of content, please select your country/region of residence. Choose International if your country is not listed.
This information will be saved using cookies. To find out more about cookies, read our Privacy Policy.
Please select your country of residence. Choose International if your country is not listed.
Our internet site may contain information that is not approved in all countries or regions. To ensure accuracy of content, it is required that you select the site which is appropriate for your country of residence.
XL BCR/ABL1/ASS consists of an aqua-labeled probe hybridizing to the ASS1 gene region at 9q34.1, an orange-labeled probe hybridizing to the ABL1 gene region at 9q34.1 and a green-labeled probe hybridizing to the BCR gene region at 22q11.2.
Probe maps are created in accordance with the intended purpose of the product. Solid colored bars do not necessarily indicate that the probe fully covers the indicated genomic region. Therefore, caution is advised when interpreting results generated through off-label use. Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale. Further information is available on request.
Chronic myelogenous leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL1 gene fusion on the derivative chromosome 22, called the Philadelphia (Ph) chromosome. The same translocation can also be found in acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) with some variation in the breakpoint region. Glivec® (imatinib mesylate) treatment targeting the BCR/ABL1 active tyrosine kinase has become a major drug in treating CML, gastrointestinal stromal tumors, and other cancers.
Deletions at the t(9;22) breakpoint regions, found in 5% of CML patients with a Ph translocation, have been associated with resistance to treatment in patients receiving tyrosine kinase inhibitors.
Normal Cell:
Two blue-orange (2BO) fusion signals and two separate green signals (2G).
Aberrant Cell (typical results):
One blue-orange (1BO), one green (1G), one blue-green-orange (1BGO) and one green-orange (1GO) fusion signal.
Aberrant Cell (typical results):
One blue-orange (1BO), two green (2G), and one green-orange (1GO) fusion signal, indicating a deletion at 9q34 in addition to a t(9;22).
Certificate of Analysis (CoA)
or go to CoA Database